Use of Fish Oils to Reduce the Frequency and Duration of Episodes of Atrial Fibrillation in Patients With Paroxysmal Atrial Fibrillation.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00232245|
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : May 30, 2013
The purpose of this study is to investigate whether fish oil supplements may reduce the frequency and duration of paroxysmal atrial fibrillation episodes.
Atrial fibrillation is a heart condition which effects a large percentage of the population .
Atrial fibrillation is a condition frequently experienced by people who have had pacemakers inserted .
Certain Pacemakers have sophisticated monitoring features that are able to recognise episodes of atrial fibrillation.
Fish oil supplements may be of benefit to patients with heart problems.Recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.
By interrogating pacemakers this study will investigate the effect of fish oil supplements on the frequency and duration of episodes of atrial fibrillation.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation||Drug: Fish oil||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||December 2003|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||January 2013|
Experimental: Fish oil
Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
Drug: Fish oil
No Intervention: Control
No fish oil exposure
- Atrial tachycardia and atrial fibrillation burden [ Time Frame: 18 months ]
- Frequency and duration of atrial tachycardia/fibrillation episodes [ Time Frame: 18 months ]
- Safety and tolerability of fish oil [ Time Frame: 18 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00232245
|Royal Melbourne hospital|
|Melbourne, Victoria, Australia, 3050|
|Principal Investigator:||Paul Sparks||Melbourne Health|